Health Care [ 4/12 ] | Life Sciences Tools & Services [ 67/74 ]
NASDAQ | Common Stock
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors.
It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products.
Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 25 | -0.07 Decreased by -163.64% | -0.07 Increased by +6.67% |
| Nov 12, 24 | 0.01 Increased by +112.91% | 0.10 Decreased by -85.80% |
| Aug 6, 24 | -0.02 Increased by +81.82% | -0.07 Increased by +71.43% |
| May 20, 24 | -0.08 Increased by +27.27% | -0.02 Decreased by -300.00% |
| Mar 5, 24 | 0.11 Increased by +375.00% | 0.23 Decreased by -52.17% |
| Nov 7, 23 | -0.11 Increased by +21.43% | -0.09 Decreased by -22.22% |
| Aug 7, 23 | -0.11 Increased by 0.00% | -0.12 Increased by +8.33% |
| May 15, 23 | -0.11 Increased by 0.00% | -0.12 Increased by +8.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 1.47 M Decreased by -95.60% | -6.12 M Decreased by -162.98% | Decreased by -415.84% Decreased by -1.53 K% |
| Sep 30, 24 | 17.13 M Increased by +N/A% | 1.28 M Increased by +112.95% | Increased by +7.45% Decreased by N/A% |
| Jun 30, 24 | 6.70 M Increased by +N/A% | -2.12 M Increased by +77.11% | Decreased by -31.68% Decreased by N/A% |
| Mar 31, 24 | 2.56 M Increased by +N/A% | -7.27 M Increased by +22.19% | Decreased by -283.98% Decreased by N/A% |
| Dec 31, 23 | 33.46 M Increased by +346.12% | 9.71 M Increased by +414.13% | Increased by +29.03% Increased by +170.41% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.85 M Increased by +8.95% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -9.28 M Decreased by -13.70% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.34 M Decreased by -2.20% | Decreased by N/A% Decreased by N/A% |